EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Urinary Liver‐Type Fatty Acid‐Binding Protein, Albuminuria, and eGFR Trajectories in Type 2 Diabetes

Hiroaki Satoh iD, Shotaro Nakamura iD, Ayako Haba, Naoki Sekine, Daisuke Sugimoto iD

Journal of Diabetes · 2026

DOI: 10.1111/1753-0407.70285 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Diabetes, 2026. Verfasst von Hiroaki Satoh und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes and Endocrinology, Juntendo University Urayasu Hospital, Urayasu, Chiba, Japan. Hauptthemen laut MEDLINE: Fatty Acid-Binding Proteins, Diabetes Mellitus, Type 2, Albuminuria, Glomerular Filtration Rate. Die Arbeit nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JSPS KAKENHI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Urinary liver‐type fatty acid‐binding protein (L‐FABP) reflects proximal tubular stress and has been proposed as a biomarker of diabetic kidney disease. We examined whether urinary L‐FABP provides information on longitudinal kidney function beyond urinary albumin‐to‐creatinine ratio (UACR).

Methods

This retrospective cohort study included patients with type 2 diabetes who had UACR and urinary L‐FABP measured simultaneously at the initial visit and underwent outpatient follow‐up. The analysis included patients with at least three eGFR measurements over at least 2 years. eGFR trajectories were evaluated using linear mixed‐effects models with random intercepts and slopes. UACR and L‐FABP were analyzed as log(1 + x )‐transformed continuous variables.

Results

The analysis included 1,031 patients (age 58.1 years; 65.1% men), with a median follow‐up of 4.76 years and a median of 10 eGFR measurements. Urinary L‐FABP correlated with UACR (Spearman ρ = 0.526; p < 0.001). Both biomarkers were independently associated with lower baseline eGFR. In a model without UACR, higher L‐FABP was associated with faster eGFR decline (−0.98 mL/min/1.73 m²/year per unit increase in log[1 + L‐FABP]; p < 0.001). After adjustment for continuous UACR, the association was attenuated and no longer significant (−0.19; 95% CI, −0.49 to 0.11; p = 0.221), whereas UACR remained independently associated with eGFR decline. Results were unchanged after further adjustment for baseline eGFR and lipid parameters.

Conclusions

Urinary L‐FABP was associated with baseline kidney impairment but did not independently predict eGFR trajectory after continuous UACR was taken into account. Urinary L‐FABP reflects kidney injury severity, although its incremental prognostic value beyond quantitatively assessed albuminuria was limited in this cohort.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fatty Acid-Binding ProteinsDiabetes Mellitus, Type 2AlbuminuriaGlomerular Filtration RateDiabetic NephropathiesHumansMiddle AgedMaleFemaleRetrospective StudiesBiomarkersAgedCreatinine

Stichwörter der Autor:innen

Type 2 diabetesalbuminuriadiabetic kidney diseaseeGFR trajectoryurinary liver‐type fatty acid‐binding protein

Substanzen

Fatty Acid-Binding ProteinsBiomarkersFABP1 protein, humanCreatinine

Autor:innen und Institutionen

  • Department of Diabetes and Endocrinology, Juntendo University Urayasu Hospital, Urayasu, Chiba, Japan.

ORCID-Profile: Hiroaki Satoh, Shotaro Nakamura, Daisuke Sugimoto

Förderung

  • JSPS KAKENHI

Zitieren

APA

Satoh, H., Nakamura, S., Haba, A., Sekine, N., & Sugimoto, D. (2026). Urinary Liver‐Type Fatty Acid‐Binding Protein, Albuminuria, and eGFR Trajectories in Type 2 Diabetes. Journal of Diabetes. https://doi.org/10.1111/1753-0407.70285

Vancouver

Satoh H, Nakamura S, Haba A, Sekine N, Sugimoto D. Urinary Liver‐Type Fatty Acid‐Binding Protein, Albuminuria, and eGFR Trajectories in Type 2 Diabetes. Journal of Diabetes. 2026. doi:10.1111/1753-0407.70285

BibTeX
@article{Satoh2026,
  author = {Satoh, Hiroaki and Nakamura, Shotaro and Haba, Ayako and Sekine, Naoki and Sugimoto, Daisuke},
  title = {Urinary Liver‐Type Fatty Acid‐Binding Protein, Albuminuria, and eGFR Trajectories in Type 2 Diabetes},
  journal = {Journal of Diabetes},
  year = {2026},
  doi = {10.1111/1753-0407.70285}
}
Kostenlos starten →